Skip to main content
. Author manuscript; available in PMC: 2016 Jul 21.
Published in final edited form as: J Neurooncol. 2014 Oct 2;121(1):159–165. doi: 10.1007/s11060-014-1617-9

Fig. 2.

Fig. 2

Neuroimaging from one patient who was classified as having progressive disease by modified World Health Organization criteria and stable disease by immune-related response criteria. a Contrast T1-weighted image pre-treatment. b Four months post-treatment showing 33 % growth of brain metastases. ce Positron-emission tomography scan 4-months post-treatment showing that areas of growth on magnetic resonance imaging are photopenic and therefore not likely to represent viable disease